Laxmi Organic Industries Ltd

- There is no explicit mention of any new fundraising through debt or equity in the provided transcript. - The company has discussed an enabling resolution for borrowing limit extension of INR 2,000 crores, which is taken year-on-year, but that does not confirm new borrowing. - Interest cost was mentioned as being well-managed, with actual borrowing costs less than the repo rate increase. - Capital expenditures are ongoing, with INR 250+ crores capitalized this fiscal primarily towards production and capacity expansion. - No direct references to new equity issuance or fresh fundraising plans were noted in the call excerpts.

- The company has capitalized over INR 250 crores in FY '23 towards increasing production and capacity across Unit 1 and Unit 2, with most investment in Unit 2. - Expected capex for FY '24 is around INR 300 crores (organic capex), kept consistent with previous years. - Capex at the Dahej land acquisition is planned but being finalized; product portfolio will build on existing successes with some augmentations. - Fluorine business capex is underway in phases, with partial capitalization done; plans to establish the base phase first, estimated to generate around EUR 25 million in revenue, followed by reinvestment into growing the business exponentially. - The company will continue investing significantly in R&D, with about 10% of PAT invested, focusing on new products, innovation, and platform expansion. - Overall strategic focus is to expand Specialty Intermediates and fluorine platform with sustained capex investments.

- Specialty Intermediates (SI) segment expected to grow via new products and markets; two large plants recently established, one stabilized, the other stabilizing. - Revenue growth in SI driven by product portfolio optimization and margin improvements, despite some slowdown in older products. - Fluorination business in ramp-up phase; FY '24 focused on establishing operations and product approvals, with revenue ramp-up expected in coming years. - FY '25 revenue targeted as a 50-50 split between Acetyls (AI) and Specialty (SP) businesses, with margin expansion primarily from specialty segments. - Export markets increasing, but company remains agnostic to domestic vs export, focusing on margin and product choice. - R&D investment to grow, fueling product pipeline and adjacencies for future growth. - Agro segment remains significant (~29% revenue), though currently facing global headwinds. - Overall, growth will come through product innovation, market expansion, and portfolio optimization, supported by continued capex and R&D.

- The company expects margin expansion primarily from specialty businesses, with EBITDA margin projected to rise from 15% to 16.5% by FY '27. - Revenue split is targeted at a balanced 50-50 between Acetyls Intermediates (AI) and Specialty Intermediates (SI) by FY '25, shifting to 45% AI and 55% SI by FY '27. - Despite muted revenue growth, profitability is expected to improve due to benefits from backward integration capex with typical payback of 3 years. - Specialty Intermediates business growth will come via new products and markets, with stabilizing plants and a strong product pipeline. - R&D investments (~10% of PAT) and organic capex (~INR 300 crores/year) will support innovation and capacity expansion. - Operational improvements and cost normalization, especially in power & fuel, are expected to aid margin recovery. - Cash flow from operations has improved significantly, indicating stronger financial health going forward.

- On page 13 (Page 14 in document), Tanushree Bagrodia confirmed that the exit run rate of Specialty Intermediates (SI) revenue is expected to sustain through FY '24 as the new plants have ramped up. - There is no explicit mention of the total current or expected order book or pending orders in the transcript. - However, Harshvardhan Goenka mentioned (Page 18) a $25 million opportunity linked to a customer that has not placed incremental orders for about 5 years due to the Miteni plant shutdown but expressed confidence in winning incremental orders based on new capabilities. - The company is stabilizing two large new plants in the SI segment, indicating ongoing order execution and future growth. - No specific quantitative order book figures are disclosed in this transcript.